Autolus Therapeutics (AUTL) Asset Writedowns and Impairment (2018 - 2025)

Autolus Therapeutics (AUTL) has reported Asset Writedowns and Impairment for 5 consecutive years, with $4.7 million the latest figure, recorded in Q4 2025.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.5 million (up 2562.04% YoY) and the FY2025 annual result came in at $12.3 million, up 2871.01% from the prior year.
• Asset Writedowns and Impairment advanced to $4.7 million in Q4 2025 per AUTL's latest filing, from $4.3 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for AUTL reached as high as $4.7 million in Q4 2025 and fell as low as $18000.0 in Q4 2023.
• A 3-year average of $2.1 million and a median of $1.5 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• The largest YoY upside for Asset Writedowns and Impairment was 503.86% in 2025 against a maximum downside of 503.86% in 2025.
• Year by year, Asset Writedowns and Impairment stood at $18000.0 in 2023, then jumped by 2200.0% to $414000.0 in 2024, then jumped by 1035.27% to $4.7 million in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $4.7 million, $4.3 million, and $2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.